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Purpose: To report the use of opaque intraocular devices in three patients with complex 
neuro-ophthalmic symptoms.
Methods: A case series of three patients with neuro-ophthalmic symptoms requiring   occlusion 
of one eye when alternative methods had failed to control symptoms. Morcher (Stuttgart, 
  Germany) opaque intraocular implants were used in all patients.
Results: All three patients observed an improvement in symptoms following opaque intraocular 
device implantation. One patient (Case 2) required multiple devices for symptom relief.
Conclusion: Opaque intraocular occlusive devices are an increasingly popular choice for 
clinicians in patients with intractable diplopia but we highlight their use in patients with other 
complex neuro-ophthalmic symptoms. We learned a number of useful lessons in these patients 
as summarized in this case series.
Keywords: intraocular lens, opaque IOL, occlusive IOL, occlusive intraocular lens, diplopia 
implant
Introduction
There are several therapeutic options available to neurologists and ophthalmologists 
for patients suffering from photophobia, intractable diplopia, image delay, or other 
neurological symptoms that require occlusion of one eye. These include corneal tat-
tooing, painted contact lenses, retrobulbar alcohol injections, and opaque intraocular 
lenses (IOLs). Opaque IOLs have been available for many years and are increasingly 
being used by clinicians for patients with intractable diplopia.1
The authors illustrate three unique scenarios involving complex neurological 
symptoms and signs that received opaque implants after other management options 
had failed. In two cases, the eye to be occluded was seeing 6/9 or better at the time 
of surgery.
We report our experience and lessons learned as summarized in Table 1, with one 
patient eventually requiring multiple devices to obtain symptomatic relief. As far as 
the authors are aware, implantation of multiple opaque devices has not previously 
been described in the literature.
Case series
Case 1
A 45-year-old female with a history of multiple sclerosis attended Accident and 
  Emergency and was diagnosed with a pupil-sparing third cranial nerve palsy in the right 
eye. She had had optic neuritis in her left eye some 8 years prior to this   attendance. 
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She was also suffering from dizziness; looking out of the left 
eye exacerbated this symptom, to the extent that she wore a 
patch over her left spectacle lens.
On examination, best-corrected visual acuities were 
6/6 in the right eye and 6/9 in the left eye. An orthoptic 
assessment revealed oscillopsia in addition to her nerve 
palsy and suggested continued patching until the symptoms 
resolved. Neurological opinion was sought from the Institute 
of Neurology (London, UK) which concluded that she had 
image delay from the previous episode of optic neuritis and 
oscillopsia from a separate episode of demyelination. Her 
symptoms did not resolve and she was fitted with a painted 
contact lens in her left eye. This was insufficient to control 
her symptoms, and she would wear sunglasses to further 
reduce light entering the eye.
Eventually she became intolerant to the contact lens so a 
clear lens extraction and an occlusive IOL implant were per-
formed under general anesthesia. An 80D Morcher (Stuttgart, 
Germany) black occlusive implant (optic diameter 6.0 mm) 
was inserted into the capsular bag. Postoperative recovery 
was uneventful. The patient remained asymptomatic until 
discharge 6 months later. No postoperative complications 
were observed.
Case 2
A 54-year-old man was referred to the Hospital Eye Service 
for an occlusive contact lens assessment. He had a 35-year 
history of double vision attributed to the loss of central fusion. 
He described developing symptoms aged 19 years after fall-
ing through a first floor window and sustaining a head injury, 
at which point he suddenly felt dizzy, experienced diplopia, 
and became unable to focus properly.
After several years he found his symptoms were worsen-
ing and began to develop headaches. He was aware of only 
using his right eye to see with, and would walk around with 
his left eye shut when possible. If he tried to use his left eye 
he would find this intolerable, often culminating in a crippling 
headache. His local optician fitted an occlusive contact lens 
to his left eye. This controlled his symptoms for several years 
until the manufacturer ceased production, at which point he 
was referred to the eye service.
On examination, best-corrected visual acuities were 6/5 in 
the right eye and 6/6 in the left eye. Orthoptic assessment 
revealed a slight left exotropia while fixating on near objects 
and concluded that there was minimal binocular function.
Left clear lens extraction and insertion of an opaque IOL 
into the capsular bag (Figure 1A) was performed using an 80D 
Morcher implant (optic diameter 6.0 mm). The patient was still 
symptomatic from light entering the eye around the edge of the 
optic, being able to count fingers with this residual peripheral 
vision and a peripheral red reflex was observed on examination. 
Two 50C Morcher castellated ring segments were subsequently 
inserted to block out this persistent peripheral light several 
months later. This relieved his symptoms, but the 80D implant 
decentered postoperatively and his symptoms returned. A third 
procedure was carried out a fortnight later at which point the 
implant was recentered, but despite this it was evident at the end 
of the operation that a red reflex persisted around the edge of 
the optic (Figure 1B). His scotopic pupil was then measured as 
6.5 mm in both eyes. A Morcher sulcus-fixated custom implant 
(Figure 1C, optic diameter 10 mm) was then inserted in front 
of the previous optic and castellated rings (all of which had 
since become intertwined, preventing removal). The patient 
no longer has diplopia though he still has perception of light. 
No postoperative complications were observed.
Case 3
A 31-year-old man suffered a ruptured anterior com-
municating artery aneurysm that was surgically clipped. 
  Postoperatively, he lost vision in his left eye – the clip 
had become displaced postoperatively, traumatizing the 
Table 1 Lessons learned. The authors learned many valuable 
lessons in the management of these patients that they wish to 
share with their colleagues
Lessons learned
1.   The need for the patient to undergo preoperative scotopic 
pupillometry. A more appropriate optic size would have been chosen 
thus avoiding the problems and repeat surgery that the second patient 
was subjected to
2.   Surgeons must be aware that these patients may have some residual 
perception of light through the sclera despite a successful procedure, 
and should be counseled preoperatively in this regard to have a 
satisfactory subjective outcome
3.   Black intraocular polymethyl methacrylate (PMMA) implants tend 
to be pro-inflammatory in the authors’ experiences, such that we 
recommend that the normal postoperative course of steroids is 
augmented to prevent postoperative uveitis
4.   The posterior vaulting of intraocular lenses designed to reduce the 
amount of posterior capsular opacification may reduce the occlusion. 
This may be prevented by using a less vaulted or non-vaulted lens. 
Pupil block may occur if the lens is placed back-to-front, although this 
would reduce the space between the pupil margin and the optical 
portion of the lens
5.   If one is to insert castellated rings to correct the problem of a 
symptomatic red reflex then the surgeon should use the model 
creating the smallest pupil size, ie, type 50E (Morcher, 3.5 mm 
effective pupil), rather than the type 50C (Morcher, 6 mm  
effective pupil) which the authors used
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Figure 1 Opaque intraocular lens insertion during several different procedures of Case 2: (A) Insertion of a Morcher (type 80D) opaque intraocular lens into the lens 
capsular bag through a scleral tunnel incision; (B) Following the second operation of Case 2, there was still a visible gap between the dual castellated rings and the central 
black intraocular lens, allowing a crescent of red reflex to show; (C) Custom-made black implant of 10 mm “optic” diameter being inserted into the eye.
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optic nerve.   Best-corrected visual acuity in the left eye was 
  perception of light, and the right eye was 6/5 uncorrected. 
Despite his low level of acuity, he found that ambient light 
caused a “shadow” in his left eye that was disabling and 
worse with both eyes open. Trial of an occlusive contact lens 
eliminated the shadows, but difficulty with insertion caused 
him to abandon their use. He was referred to the hospital eye 
service for consideration of an occlusive implant.
On examination, his visual acuities were as described 
above. The left eye demonstrated a dense relative afferent 
pupillary defect. Anterior segment examination was normal. 
The optic nerve was atrophic and the retinal blood vessels 
were attenuated. The right eye was normal. An infrared pup-
illometer was used on the left eye, measuring mesopic and 
scotopic diameters of 4 mm and 6 mm, respectively.
The patient underwent uncomplicated left clear lens 
extraction through a superior scleral tunnel wound under 
general anesthesia. An 81D Morcher biconvex implant 
(optic diameter 7.0 mm) was inserted into the capsular 
bag. Routine topical anti-inflammatory and antibiotic cover 
was prescribed postoperatively. At the 1-month review, 
he perceived no light in the left eye and reported a marked 
improvement in his symptoms, which was maintained at the 
6-month follow-up.
Discussion
This paper addresses three patients who benefited from 
opaque IOL implants. In two of these cases, the visual acu-
ity of the eye to be occluded was 6/9 or better at the time 
of surgery.
Absence of central fusion, image delay, and photophobia 
were all symptoms demonstrated by these patients and were 
addressed as much as possible preoperatively with orthoptic 
and orthotic means. Given the quasi-permanent nature of the 
implant and the risk of serious complications, it is paramount 
to consider noninvasive options first. These include corneal 
tattooing2,3 and occlusive contact lenses.4 Given that the pupil 
size is fixed with corneal tattooing, and that the appearance is 
only really satisfactory when viewed in the primary position 
(ie, when not subject to parallax), this therapeutic modality 
is only applicable in cases of poor cosmesis. The patients 
in this series were all so acutely sensitive to the smallest 
amount of light entering the eye that corneal tattooing would 
most likely be insufficient to cure their symptoms and car-
ries a risk of potential corneal toxicity.5 More recently, Alió 
et al has reported a novel femtosecond-assisted approach 
to corneal tattooing that is more precise, safer, and easier 
to perform.6 They demonstrated the use of new micronized 
mineral pigments to be safe at 2-year follow-up although they 
recommended further studies would be necessary to assess 
the pigment’s longer term stability.
Occlusive contact lenses were trialed in all three patients. 
The first patient became intolerant to the contact lens. The 
second patient could only wear one particular type of lens, 
which subsequently became unavailable due to manufactur-
ing reasons. The third patient was unable to master insertion 
of the lens.
We have described our experience of opaque IOL 
implantation in three patients with unique visual symptoms. 
No patient experienced any postoperative complications at 
the 6-month follow-up. Others have reported implantation 
of these IOLs for other indications including unsightly 
  leukocoria7 and aniridia,8 however, clinicians are increas-
ingly using them for intractable diplopia9–11 in association 
with lens extraction. Landesz et al has reported the use of 
a custom-made opaque phakic IOL for diplopia following 
traumatic sixth nerve palsy12 but found a difference of 18.6% 
in mean endothelial cell density 14-years postoperatively. 
Other complications reported with phakic IOLs include pig-
ment dispersion, glaucoma, uveitis, and pupil ovalization that 
could let additional light in through the pupil.13 We therefore 
prefer insertion of the opaque IOL into the bag, which carries 
less risk of uveitis, glaucoma, endothelial cell loss, or risk of 
cataract formation if a phakic IOL were used.
Normally, residents in the UK are invited to their 
optometry practice for a biennial eye exam, during which 
basic screening exams are carried out (diabetes, glaucoma). 
Patients with posterior segment pathology are often picked 
up in this manner. Obviously, if patients have a fundus-
obscuring diplopia implant in situ, this is not possible. In 
order not to miss any life-threatening posterior segment 
pathology such as a neoplasm, it seems reasonable to conduct 
biennial B-scan ultrasound on these patients. Patel et al has 
recently reported the use of optical coherence tomography 
to successfully image the macula through an opaque IOL.14
Conclusion
This case series illustrates three unique patients who even-
tually had a satisfactory outcome from the insertion of 
occlusive implants. Unacceptable cosmesis is certainly an 
indication for this treatment modality, but intractable central 
lesions causing the disabling symptoms which these patients 
exhibited mean that this procedure should figure at the 
forefront of neurologists’ and ophthalmologists’ treatment 
plans should conservative measures fail. Two of our patients 
had been long-suffering which was thought to be functional 
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in nature. We have learned a number of useful lessons as 
summarized by Table 1.
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